Skip to main content

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference.

The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1.

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Contacts

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com



Media:

Email: media@evolus.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  199.94
+1.15 (0.58%)
AAPL  258.52
+2.74 (1.07%)
AMD  204.49
-2.83 (-1.36%)
BAC  53.04
+0.49 (0.93%)
GOOG  303.70
-2.32 (-0.76%)
META  639.61
-0.16 (-0.03%)
MSFT  399.57
-1.75 (-0.44%)
NVDA  182.51
-0.30 (-0.16%)
ORCL  158.21
-1.93 (-1.21%)
TSLA  409.38
-8.06 (-1.93%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.